发明名称 |
BIOLOGICAL MARKERS PREDICTIVE OF ANTI-CANCER RESPONSE TO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE INHIBITORS |
摘要 |
The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with an IGF-1R kinase inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by an IGF-1R kinase inhibitor, comprising assessing whether the tumor cell has undergone an epithelial to mesenchymal transition (EMT), by determining the expression level of epithelial and/or mesenchymal biomarkers, wherein tumor cells that have undergone an EMT are substantially less sensitive to inhibition by IGF-1R kinase inhibitors. Improved methods for treating cancer patients with IGF-1R kinase inhibitors that incorporate the above methodology are also provided. Additionally, methods are provided for the identification of new biomarkers that are predictive of responsiveness of tumors to IGF-1R kinase inhibitors. Furthermore, methods for the identification of agents that restore the sensitivity of tumor cells that have undergone EMT to inhibition by IGF-1R kinase inhibitors are also provided. pErk, HER3 and pHER are also demonstrated to be effective biomarkers for predicting sensitivity of tumor cells to IGF-1R kinase inhibitors. |
申请公布号 |
WO2009045389(A3) |
申请公布日期 |
2009.07.02 |
申请号 |
WO2008US11299 |
申请日期 |
2008.09.29 |
申请人 |
OSI PHARMACEUTICALS, INC.;BUCK, ELIZABETH, A.;HALEY, JOHN, D. |
发明人 |
BUCK, ELIZABETH, A.;HALEY, JOHN, D. |
分类号 |
G01N33/50;G01N33/574 |
主分类号 |
G01N33/50 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|